ation of:



McKearn, J.P. et al.

Serial No.:

09/857,873

Filed:

October 5, 2001

Title:

METHOD OF USING A CYCLOOXYGENASE-2 INHIBITOR AND ONE

OR MORE ANTINEOPLASTIC AGENTS AS A COMBINATION

THERAPY IN THE TREATMENT OF NEOPLASIA

Group Art Unit:

1614

Examiner:

M.G. Hartley

Confirmation No.: 2817

Docket No.:

6794F-000036/US/01

Client Ref.:

3167/4Z/US

## **CERTIFICATE OF MAILING**

I certify that this paper, together with any attachments thereto, is being deposited with the United States Postal Service with sufficient postage as FIRST CLASS MAIL in an envelope addressed to: Commissioner for Patents, Mail Stop AF, P.O. Box 1450, Alexandria, VA 22313-1450, on August 17, 2004.

AF/ 1614

August 17, 2004

Commissioner for Patents Mail Stop AF P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## AMENDMENT AFTER FINAL ACTION UNDER 37 CFR §1.116

(AMENDMENT C)

This paper is responsive to the Office Action dated May 18, 2004 in the above-referenced application, which Action was made final. Amendment of the application is requested to cancel claims and to present rejected claims in better form for consideration on appeal. Allowance of all claims remaining in the application is respectfully requested following entry of the present amendment.

This paper is submitted within the 3 months shortened statutory period set for reply, accordingly no fee for extension of time is believed payable.

Serial No. 09/857,873 6794F-000036/US/01 (3167/4Z/US) Amendment after final action under 37 CFR §1.116 (Amendment C) August 17, 2004

By the present amendment, the total number of claims pending in the application is decreased from 29 to 5 and the number of independent claims is decreased from 7 to 3. No excess claim fee is believed payable.

Amendments IN THE CLAIMS are reflected in the listing of claims which begins on page 3 of this paper.

REMARKS on the present amendment begin on page 4 of this paper.